These results indicate that MM cells recruit macrophage infiltration toward M2 polarization by secreting CCL3, and that the CCR5 inhibitor MVC enhances the sensitivity of Bortezomib treatment. This evidence concerns the gene CCR5 and Miyoshi myopathy.